secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001193125-26-042812
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q1 FY2026 net loss $11.9M ($0.42/sh); pipeline advances with zelicapavir and new immunology programs
--------------------------------------------------------------------------------

- Revenue of $18.6M from AbbVie royalties, up 9% vs $17.0M YoY; net loss narrowed to $11.9M from $22.3M.
- Cash & securities $241.9M; runway expected into fiscal 2029.
- Zelicapavir Phase 2b RSVHR showed 6.7-day improvement in symptom resolution for high-risk adults; Phase 3 enabling activities ongoing.
- New MRGPRX2 immunology program introduced; development candidate selection expected in 2H 2026.
- EDP-978 (oral KIT) IND on track for Q1 2026; EPS-3903 (oral STAT6) IND targeting 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/0001193125-26-042812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-042812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer